Healthcare Private Placement and M&A Transactions Review

Strategy | Financing | Macro & Markets

Share Silverwood Weekly Healthcare Market Update

Private Placement / Financing Transactions

Function Health: The company raised $450 million of venture funding from General Catalyst on July 30, 2026. The company is a provider of preventive healthcare services through comprehensive laboratory testing and personalized health insights.Qualified Health: The company raised $125 million of Series B venture funding in a deal led by New Enterprise Associates on July 29, 2026. The company is a developer of generative AI infrastructure for deploying, evaluating and monitoring clinical AI applications.Claris Bio: The company raised $118 million of Series B venture funding in a deal led by Catalio Capital Management and Samsara BioCapital on July 28, 2026, putting the company’s pre-money valuation at $70 million. The company is a developer of a topical formulation technology designed to treat orphan ophthalmic disorders.Xeltis: The company raised EUR 70.5 million through a combination of debt and equity on July 28, 2026. EUR 33 million of venture funding was led by Horizon 3 Healthcare with participation from other investors. The company is a developer of restorative cardiovascular implants that regenerate into living blood vessels and heart valves.Ratio Therapeutics: The company raised $70 million of Series C venture funding from Bristol-Myers Squibb, Wasatch Group, and Catalio Capital Management on July 31, 2026. The company is a developer of targeted radiopharmaceuticals designed to improve cancer treatment through precision medicine.Alpheus Medical: The company raised $60.4 million in Series B venture funding in a deal led by HealthQuest Capital and Samsara BioCapital on July 30, 2026, putting the company’s pre-money valuation at $88 million. The company is a developer of focused ultrasound therapies for glioblastoma and other brain tumors.Trailhead Biosystems: The company raised $40.6 million of venture funding in the form of convertible debt in a deal led by MAK Capital on July 30, 2026. The company is a developer of iPSC-derived research cell products and differentiation technologies designed to enable consistent and scalable human cell models.Instylla: The company raised $34.7 million of Series C venture funding from undisclosed investors on July 27, 2026, putting the company’s pre-money valuation at $178 million. The company is a developer of liquid embolic devices for minimally invasive vascular embolization procedures.NextPoint: The company raised $33.7 million of venture funding from undisclosed investors on July 29, 2026. The company is a developer of precision therapeutics designed to treat cancer through targeted immunotherapy approaches.Epitel: The company raised $26 million of Series B venture funding in a deal led by Catalyst Health Ventures and Genoa Ventures on July 28, 2026, putting the company’s pre-money valuation at $62 million. The company is a developer of wearable EEG monitoring devices for detecting and monitoring neurological disorders.Roger Healthcare: The company raised $23.7 million of Series A venture funding from undisclosed investors on July 28, 2026, putting the company’s pre-money valuation at $128.2 million. The company is a developer of AI-powered clinical documentation software for home healthcare providers.Qureight: The company raised $20 million of Series B venture funding in a deal led by Molten Ventures on July 29, 2026. Hargreave Hale AIM VCT 2, XTX Ventures, Guinness Ventures, Ascension and Meltwind Advisory also participated in the round. The company is a developer of a clinical data curation and analytics platform designed to combine technology and life sciences to accelerate drug development.SoundHealth: The company raised $12.25 million of Series A venture funding in a deal led by ShangBay Capital on July 29, 2026. The company is a developer of sound-based digital therapeutics for nasal congestion and upper respiratory conditions.Biosceptre: The company raised GBP 8.4 million of venture funding from undisclosed investors on July 27, 2026. The company is a developer of antibody-based immunotherapies targeting multiple solid tumors.Predisurge: The company raised EUR 6 million of venture funding from M.I.Tech on July 28, 2026. The company is a developer of AI-enabled procedural planning software for cardiovascular interventions.Genomenon: The company raised $6 million of venture funding from undisclosed investors on July 30, 2026. The company is a developer of genome interpretation software designed to improve cancer diagnosis and treatment.Mirae: The company raised $5.4 million of venture funding in a deal led by Oxford Science Enterprises on July 28, 2026. The company is a developer of AI-enabled digital therapeutics for inflammatory bowel disease and gastrointestinal disorders.Core Biomedicine: The company raised an undisclosed amount of Series A venture funding in a deal led by Elikon Venture and UTokyo Innovation Platform Company on July 28, 2026, putting the company’s pre-money valuation at $24 million. The company is a developer of precision oncology therapeutics designed to target core lineage-dependent pathways in cancer.Trace Biosciences: The company raised an undisclosed amount of venture funding from Axogen on July 29, 2026. The company is a developer of nerve-targeted fluorescent contrast agents designed to guide surgeries and eliminate surgical nerve damage.

M&A Transactions

Avanos Medical / American Industrial Partners: The company was acquired by American Industrial Partners through an estimated $1.3 billion public-to-private LBO on July 27, 2026. The company is a developer of medical technology products for pain management and digestive health.Forte Biosciences / Argenx: The company reached a definitive agreement to be acquired by Argenx for approximately $1 billion on July 27, 2026. The company is an operator of a clinical-stage biopharmaceutical business that is advancing through preclinical trials its product, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune-related indications.FireFly Bio / Johnson & Johnson: The company was acquired by Johnson & Johnson for $1 billion on July 29, 2026. The company is an operator of an antibody-drug conjugate-based healthcare platform intended to treat cancer using degradable proteins.InfoRLife / BC Partners: The company entered into a definitive agreement to be acquired by BC Partners through an estimated $750 million LBO on July 28, 2026. The company is a manufacturer of ready-to-administer intravenous infusion products for healthcare providers.Obagi Cosmeceuticals / Bridgepoint Group: The company, a subsidiary of Waldencast, was acquired by Bridgepoint Group through a $460 million LBO on July 30, 2026. The company is a developer and retailer of physician-dispensed skincare products.Sanara MedTech / Mimedx Group: The company reached a definitive agreement to be acquired by Mimedx Group for $369 million on July 29, 2026. The company is a developer of technologies designed to improve clinical outcomes and reduce healthcare expenditures in the surgical market.Yarrow Bioscience / VYNE Therapeutics: The company acquired VYNE Therapeutics through a reverse merger for $200 million resulting in the combined entity trading on the Nasdaq Capital Market under the ticker symbol YARW on July 27, 2026. The company is an operator of a biopharmaceutical business intended to create novel therapies for chronic and inflammatory diseases.Oak Hill Bio / Research Alliance III: The company reached a definitive agreement to acquire Research Alliance III (NAS:RACC) through a reverse merger on July 29, 2026. The company is a clinical-stage developer of therapies for rare endocrine and metabolic diseases.Standard BioTools / Multiplex Bio: Multiplex Bio reached a definitive agreement to acquire the Mass Cytometry Business of Standard BioTools for approximately $10 million on July 28, 2026. The company is a manufacturer of mass cytometry instruments for single-cell analysis and spatial proteomics.Anaquant / Clean Cells: The company was acquired by Clean Cells, a subsidiary of Clean Biologics, for an undisclosed amount on July 30, 2026. The company is a provider of mass spectrometry-based bioanalytical testing services for biotechnology and pharmaceutical companies.BIO-CAT / Lallemand: The company was acquired by Lallemand for an undisclosed amount on July 31, 2026. The company is a developer and manufacturer of enzymes, probiotics and microbial products for life sciences, food and industrial applications.Caldera Therapeutics / Synlogic: The company reached a definitive agreement to Synlogic through a reverse merger, resulting in the combined entity trading on the Nasdaq Market under the ticker CALD on July 29, 2026. The company is a clinical-stage developer of bispecific antibody therapies for inflammatory bowel disease.MYOS / PetIQ: The company was acquired by PetIQ, via its financial sponsors Bansk Group and Ares Management, through an LBO on July 29, 2026 for an undisclosed amount. The company is a producer of muscle health nutritional supplements for humans and animals.

Source: Pitchbook Data, Inc.
Connect on LinkedIn with Jonathan Hodson-Walker